The stock of Nautilus Biotechnology Inc (NASDAQ: NAUT) has decreased by -18.18 when compared to last closing price of 1.43. Despite this, the company has experienced a -26.88% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-31 that Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research’s esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research’s esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging
Is It Worth Investing in Nautilus Biotechnology Inc (NASDAQ: NAUT) Right Now?
The stock has a 36-month beta value of 1.06. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NAUT is 57.73M, and at present, short sellers hold a 0.49% of that float. On February 28, 2025, the average trading volume of NAUT was 129.50K shares.
NAUT’s Market Performance
The stock of Nautilus Biotechnology Inc (NAUT) has seen a -26.88% decrease in the past week, with a -35.00% drop in the past month, and a -51.25% fall in the past quarter. The volatility ratio for the week is 8.69%, and the volatility levels for the past 30 days are at 6.44% for NAUT. The simple moving average for the last 20 days is -27.84% for NAUT stock, with a simple moving average of -50.57% for the last 200 days.
Analysts’ Opinion of NAUT
Many brokerage firms have already submitted their reports for NAUT stocks, with Goldman repeating the rating for NAUT by listing it as a “Sell.” The predicted price for NAUT in the upcoming period, according to Goldman is $1.75 based on the research report published on December 05, 2024 of the previous year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see NAUT reach a price target of $6. The rating they have provided for NAUT stocks is “Buy” according to the report published on June 27th, 2024.
Jefferies gave a rating of “Hold” to NAUT, setting the target price at $3 in the report published on June 03rd of the previous year.
NAUT Trading at -32.95% from the 50-Day Moving Average
After a stumble in the market that brought NAUT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.14% of loss for the given period.
Volatility was left at 6.44%, however, over the last 30 days, the volatility rate increased by 8.69%, as shares sank -33.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.65% lower at present.
During the last 5 trading sessions, NAUT fell by -26.88%, which changed the moving average for the period of 200-days by -58.21% in comparison to the 20-day moving average, which settled at $1.6215. In addition, Nautilus Biotechnology Inc saw -30.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAUT starting from MARY GODWIN, who proposed sale 38,337 shares at the price of $1.94 back on Dec 17 ’24. After this action, MARY GODWIN now owns shares of Nautilus Biotechnology Inc, valued at $74,263 using the latest closing price.
MARY GODWIN, the Officer of Nautilus Biotechnology Inc, proposed sale 35,000 shares at $2.13 during a trade that took place back on Dec 09 ’24, which means that MARY GODWIN is holding shares at $74,588 based on the most recent closing price.
Stock Fundamentals for NAUT
Current profitability levels for the company are sitting at:
- -9.56 for the present operating margin
- 0.22 for the gross margin
The net margin for Nautilus Biotechnology Inc stands at -8.55. The total capital return value is set at -0.31. Equity return is now at value -28.04, with -24.29 for asset returns.
Based on Nautilus Biotechnology Inc (NAUT), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -1.86. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -25.37.
When we switch over and look at the enterprise to sales, we see a ratio of 21.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.65.
Conclusion
To sum up, Nautilus Biotechnology Inc (NAUT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
